The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary by Iversen, Allan et al.
  Current Cardiology Reviews, 2008, 4, 293-299 293
  1573-403X/08 $55.00+.00  ©2008 Bentham Science Publishers Ltd.
The Optimal Route of Administration of the Glycoprotein IIb/IIIa   
Receptor Antagonist Abciximab During Percutaneous Coronary   
Intervention; Intravenous Versus Intracoronary 
Allan Iversen
*, Søren Galatius and Jan S. Jensen 
Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark 
Abstract: The use of the glycoprotein (GP) IIb/IIIa receptor antagonist Abciximab has over the years become an impor-
tant part of the anticoagulant regimen in patients with acute coronary syndrome undergoing percutaneous coronary inter-
vention. Abciximab is a potent inhibitor of platelet aggregation and thrombus formation, but other mechanisms, such as 
suppression of the inflammatory pathways, have also been proposed to contribute to the benefits of Abciximab. 
The optimal route of administration, i.e. intravenous versus intracoronary, of the first dose has been questioned, but only 
tested in small, non-randomised and retrospective studies or studies with short follow-up. No definite conclusion can be 
made based on these studies 
In this review we present the current knowledge published about the intracoronary administration of Abciximab including 
the mechanisms behind the potential beneficial effects, and the safety. The emphasis will be on clinical trials rather than 
on studies on the pharmacological mechanisms, as the latter have been reviewed thoroughly elsewhere. 
Our conclusion from this present review is that randomized trials of intracoronary versus intravenous bolus of Abciximab 
are needed.  
Key Words: Abciximab, coronary heart disease, glycoprotein IIb/IIIa, intracoronary, intravenous, percutaneous coronary inter-
vention.  
INTRODUCTION 
  Cardiovascular diseases are responsible not only for the 
majority of deaths in the United States [1] and Europe, but 
also for a large proportion of the hospital expenses. Athero-
sclerosis in the coronary arteries leading to acute coronary 
syndrome (ACS) accounts for the majority of cardiovascular 
diseases and massive resources have been put into the man-
agement of ACS. Along with improvement of mechanical 
devices such as stents, focus is directed to periprocedural 
anticoagulants, so-called facilitated percutaneous coronary 
intervention (PCI). One class of drug in facilitated PCI is the 
glycoprotein (GP) IIb/IIIa receptor antagonist of which Ab-
ciximab is one of them. Abciximab was released for com-
mercial use in February 1995. 
  Numerous interventional trials have proven Abciximab 
effective in reducing death, myocardial infarction (MI) and 
revascularization in patients with ACS. These trials, the first 
of them published in the 1990ies, and the latest ISAAR RE-
ACT 2 which was published in 2008 [2], are based on the 
use of intravenous (iv) Abciximab, exclusively. However, 
during the recent years, both a number of case-reports and a 
few smaller non randomised studies have been published, 
suggesting that intracoronary (ic) administration of Abcixi-
mab may be a better alternative. 
  The main purpose of this article is to review published 
clinical studies presenting data on the use of intracoronary 
administration of Abciximab.  
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BACKGROUND - CLINICAL STUDIES ON ABCIXI-
MAB  
  It has been known for years that activation followed by 
aggregation of platelets to a thrombus is the major patho-
physiological player causing ACS [3,4]. The first event in a 
cascade of events leading to ACS is the rupture of an athero-
sclerotic plaque in a coronary artery, thereby uncovering 
subendothelial connective tissue in the arterial wall to the 
components of the blood, especially platelets. On the platelet 
surface the glycoprotein IIb/IIIa receptor is expressed, which 
is one of the surface proteins responsible for platelet-aggre-
gation. Abciximab irreversibly inhibits this aggregation.  
  Previous studies have proven the beneficial effect of Ab-
ciximab in ACS and PCI. The first large-scaled, multicenter, 
randomized, double-blind trial was the Evaluation of 7E3 for 
the Prevention of Ischemic Complication study (EPIC) pub-
lished in 1994 [5]. In this study 2,100 high-risk patients (un-
stable angina pectoris (UAP), ST-elevation MI (STEMI) or 
high-risk coronary lesions) undergoing PCI received iv bolus 
of Abciximab or placebo followed by a 12-hour iv-infusion 
of either Abciximab or placebo. The results were convincing 
in advantage of Abciximab with respect to the composite 
end-point consisting of death, MI or revascularization dem-
onstrating a significant reduction from 12.8% to 8.3% after 
30 days. Even after 6 months and 3 years there was a signifi-
cant reduction in the composite end-point among those 
treated with Abciximab from 35.1% to 27.0% [6] and 47.2% 
to 41.1% [7], respectively. In the 30-day period a doubling of 
major bleeding was observed in the active drug group from 
6.6% to 14.0% [8] - one major problem in adding an extra 
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  The EPIC trial was followed by Evaluation in Percutane-
ous Transluminal Coronary Angioplasty to Improve Long-
Term Outcome with Abciximab GP IIb/IIIa Blockage – 
EPILOG [9] and Evaluation of Platelet IIb/IIIa Inhibitor for 
Stenting – EPISTENT [10,11]. In EPILOG the same com-
posite end-point as in EPIC was used, but the enrolement 
criteria were expanded to include low-risk patients as well as 
high-risk patients. Not only did the investigators randomize 
patients to either Abciximab or placebo. An additional regi-
men of low-dose heparin (70 U/kg; activated clotting time 
(ACT)200 sec) versus standard heparin (100 U/kg; 
ACT300 sec) was tested. Since the EPIC trial convincingly 
proved the effect of Abciximab in patients with UAP, 
STEMI or planned PCI, those patients were excluded from 
the EPILOG trial. 4,800 patients were planned to be en-
rolled, but the study was terminated prematurely (with nearly 
2,800 patients enrolled) because an interim analysis at 30 
days showed a 56% reduction with respect to the composite 
end-point among those receiving Abciximab (Abciximab iv-
bolus followed by 12 hours of iv-infusion regardless of stan-
dard- or low-dose heparin) compared to those receiving pla-
cebo. The beneficial outcome in this treatment group per-
sisted after 6 months follow-up [12]. No differences were 
found in bleeding complications. The results were used to 
extrapolate the results from EPIC to low-risk patients under-
going PCI. In the EPISTENT trial 2,400 patients were ran-
domized to stenting plus Abciximab, stenting plus placebo or 
balloon-angioplasty plus Abciximab. Follow-up was at 30 
days and a composite end-point of death, MI or need for ur-
gent revascularization was used. The study showed a reduc-
tion in the composite end-point from 10.8% in the stent plus 
placebo to 5.3% in the stent plus Abciximab. In the balloon 
plus Abciximab group 6.9% reached the composite end-
point. Abciximab was found to be safe with respect to major 
bleeding. 
 Cho  et al. made a pooled analysis of the three studies 
mentioned above [13] to demonstrate whether Abciximab 
had the same beneficial effect in both men and women. No 
differences were found. As part of their analysis a multivari-
ate logistic regression was performed. Gender was not found 
to be associated to either increased or reduced risk of the 
compositeend-point.Furthermore,it was found in this pooled 
analysis (n=6,995) that the use of Abciximab was associated 
with a 49% relative risk reduction of reaching the end-point.  
  In C7E3 Fab Antiplatelet Therapy in Unstable Angina - 
CAPTURE, another interventional study, the question of 
whether Abciximab should be started up front and prior to 
PCI, was investigated [14]. In this study, Abciximab or pla-
cebo was started as iv-infusion 18-24 hours prior to PCI in 
contrast to earlier regimes in which Abciximab was given as 
an iv-bolus, at the time of PCI. Because of a 29% reduction 
of the composite end-point at 30 days in the Abciximab arm, 
the study was terminated prematurely, when 1,265 (of ex-
pected 1,400) patients had been enrolled. However, at 6 
months no differences between Abciximab and placebo were 
observed. Based on this, pre-PCI Abciximab-infusion is at 
generally not recommended. Most trials on GP IIb/IIIa in-
hibitors have been conducted on patients scheduled for PCI. 
In 2002 Boersman et al. published a meta-analysis of trials 
with patients receiving GP IIb/IIIa inhibitors and not rou-
tinely scheduled for PCI [15]. The main findings of this large 
analysis (n=31,402) was a 9 % reduction in death and MI in 
patients receiving GP IIb/IIIa inhibitors.  
  There have been some safety concerns about the use of 
Abciximab. Especially with respect to both acute [16,17] and 
delayed [18] thrombocytopenia leading to excess risk of 
bleeding. Baseline characteristics such as low body weight, 
high age and low baseline platelet counts increase the risk of 
thrombocytopenia [19]. 
  Since Abciximab is a human chimeric Fab fragment anti-
body the question of development of hypersensitivity has 
been investigated. Tcheng et al. [20] found that in patients 
receiving a second dose of Abciximab, the number of human 
antichimeric antibody-positive rose from 4.8 % before first 
administration to 19.0 % after second administration. How-
ever, this had no influence on clinical outcome. For the same 
reason Madan et al. [21] investigated if the efficacy would 
decline when Abciximab was given more than once, and 
found no such relationship.  
  In general Abciximab is thought to be safe with respect 
to minor and major bleedings, despite an increase in the inci-
dence of bleedings in some studies [8,22-26]. The same is 
observed for the risk of stroke [27], both compared to pla-
cebo and to another GP IIb/IIIa inhibitor, Eptifibatide [28].
  Oral GP IIb/IIIa inhibitors have been considered and 
tested (EXCITE [29], OPUS-TIMI 16 [30], SYMPHONY 
[31], 2
nd SYMPHONY [32] and BRAVO [33]), all with ad-
verse outcomes [31,34,35]. In a meta-analysis including the 
above mentioned trials Chew et al. [35] found a 37 % in-
crease in mortality in oral GP IIb/IIIa inhibitors compared to 
placebo. The results were surprising, since one would expect 
a similar positive effect as seen in iv administration. In 2004 
Sy et al. [36] presented several hypothesis regarding these 
finding, but no trials on oral GP IIb/IIIa inhibitors have been 
published since. 
  An important issue, which must be taken into considera-
tion when discussing the use of GP IIb/IIIa inhibitors, is the 
use of other anticoagulants, such as thienopyridines and 
newer agents as Prasugrel and Cangrelor. In 2008 the ISAR-
REACT 2 trial 1 year follow up was published [2]. In this 
trial all patients (n=2,022) with non-ST-segment elevation 
acute coronary syndromes received 600 mg clopidogrel pre-
treatment before PCI. Approximately one third received Ab-
ciximab iv in relation to PCI. After one year the primary end 
point of death, MI, or target vessel revascularization (TVR) 
was reached in 23.3 % of patients allocated to Abciximab vs.
28.0 % of patients allocated to placebo (P=0.0012). The were 
no safety issues [37]. Regarding newer agents one must con-
sider their potential interaction with GP IIb/IIIa inhibitors 
also in the context of iv vs. ic administration. 
  In the latest European guidelines for treatment of ACS 
the use of GP IIb/IIIa inhibitors are described, but only trials 
concerning the iv route have been taken into consideration in 
the ECS recommendations [38]. This is also the case for the 
American Heart Association guidelines [39,40]. 
  The pharmacological mechanism of Abciximab has re-
cently been described [41] and are summarised in Table 1
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  Most important in this setting probably is the fact that 
high local concentration of Abciximab seems to have a 
thrombolytic effect [42]. Marciniak et al. have shown that 
low concentrations of Abciximab [1.3-3 Kg/ml] prevents 
further platelet aggregation in a thrombus, while high con-
centrations ( 10 Kg/ml) have the ability to disperse an al-
ready formed thrombus.  
  Despite this iv administration of Abciximab is generally 
recommended, although there may be arguments for ic bolus 
administration. We therefore reviewed clinical studies and 
case reports on this issue.  
METHODS 
  A search in PubMed and EMBASE was performed using 
the search criteria Abciximab, Reo-Pro, glycoprotein IIb/IIIa, 
intracoronary, acute coronary syndrome, percutaneous coro-
nary intervention and coronary angioplasty. In an effort to 
identify further published trials we searched reference lists 
and to identify ongoing trials we searched in www.clinical 
trials.gov, and Cochrane Central Register of Controlled Tri-
als (CENTRAL) was consulted for reviews. The results were 
narrowed down to include case reports and clinical trials 
testing or describing the issue of intracoronary administra-
tion of Abciximab. 
TRIALS EVALUATING INTRAVENOUS VS. INTRA-
CORONARY ABCIXIMAB 
  The first reports on ic administered Abciximab were pre-
sented in 1997. Bailey et al. described a small study of 12 
patients with ´unstable clinical syndromes´ (defined as: su-
bacute stent thombosis, UAP or Post-MI) who received ic 
delivered Abciximab [43]. Inspired by studies in which 
urokinase [44] and heparin [45] was given ic with positive 
results on outcome, Bailey treated 12 patients with an-
gioscopic verified thrombus with 5-10 mg ic delivered Ab-
ciximab in addition to orally given aspirin and iv adminis-
tered heparin. The ic administered Abciximab was not fol-
lowed by iv infusion. In 11 of 12 patients resolution of the 
thrombus was observed after performing re-angioscopy. The 
patients were then treated with mechanical revascularization. 
The number of patients was too small to evaluate major 
complications such as STEMI, Non-STEMI, death and 
emergency coronary artery by-pass grafting (CABG). In 
1999 Bartorelli et al. reported a case [46] in which Abcixi-
mab was administered ic in a STEMI-patient with occlusion 
of proximal LAD. Treatment with systemic thrombolysis and 
angioplasty was attempted without success prior to the ic 
delivery of Abciximab. After ic administration of the GP 
IIb/IIIa blocker complete resolution of the thrombus was 
seen with subsequent TIMI 3 flow. No bleeding complica-
tions were described. Through 1999 to 2004 several cases 
and small studies on the matter were published. 
  In 2000 Baron et al. investigated the possibility of coat-
ing coronary stents with Abciximab (c7E3-Fab) and found 
that the drug eluted slowly and in a predictable manner and 
significantly inhibited platelet deposition in vitro [47]. Ab-
ciximab-eluting stents for commercial use is to our knowl-
edge not available. Barsness et al. found that in 57 patients 
with >60% stenosis in a saphenous vein graft that required 
percutaneous intervention, local delivery of Abciximab re-
sulted in significantly reduced thrombus size evaluated on 
angiogram. One third of the patients had no visible thrombus 
at the initiation of the procedure, while two thirds showed no 
signs of thrombus after local delivery of Abciximab. At the 
end of the procedure 89% of the patients were without 
thrombus [48].  
  In 2003 at the convention of Transcatheter Cardiovascu-
lar Therapeutics - TCT, Kennon et al. presented in abstract 
form a case series of 6 patients with no-reflow after PCI 
treated with local delivery of Abciximab. All patients 
showed improved TIMI flow after Abciximab [49]. The use 
of ic administered Abciximab becomes more accepted during 
this period, in spite of the fact that no prospective, random-
ized trials have been conducted so far. In a case from `clini-
cal Decision Making´ in the Journal of Invasive Cardiology 
the authors had asked how to manage a 63-year-old female 
with NSTEMI [50]. Amongst the comments from colleagues 
especially one is interesting in this context. Kereiakes et al.
Table 1.  Mechanisms of Abciximab 
• IIb/IIIa platelet glycoprotein blockade determining platelet aggregation inhibition; 
• active thrombolytic effect by means of partial displacement of platelet-bound fibrinogen; 
• inhibition of platelet-induced generation of thrombin reducing granule release: it results in reduced levels of platelet-derived inhibition of fibrinolysis
such as PAI-1 and 2-anti-plasmin; 
• Blokade of the binding of the factor XIIIa to platelets, thereby diminishing crosslinking of both fibrin strands and 2-anti-plasmin to fibrin and re-
duction of clot retraction; 
• blockade of the activated Mac-1 on monocytes and Mac-1-expressing THP-1 cells; 
• inhibition of fibrinogen binding to Mac-1 preventing formation of leukocyte/leukocyte or leukocyte/platelet aggregates; 
• inhibition of Mac-1-mediated monocyte adhesion on ICAM-1; 
• inhibition of factor X binding to Mac-1 and Mac-1-mediated conversion of factor X to Xa; 
• blockade of Vb3 vitronectin receptor preventing smooth muscle cells migration and intimal hyperplasia following vascular injury, 
• inhibition of platelet adhesion to osteopontin in atherosclerotic plaque and platelet-mediated thrombin generation via blokade of Vb3 receptor.
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suggest that bolus of Abciximab (0.25 mg/kg) should be ad-
ministered into the target vessel, if the diagnostic angiogram 
showed impaired coronary flow (TIMI 1-2). PCI should then 
be performed after 48 hours. Lee et al. describes a case re-
port on a 60-year-old man in whom ic Abciximab (instead of 
using mechanical thrombectomy) was used successfully to 
dissolve a thrombus that appeared during PCI [51]. In 2007 
Carey and colleagues presented a case in which a STEMI-
patient, who underwent PCI, was given ic Abciximab in ad-
dition to mechanical thrombectomy (aspiration and translu-
minal extraction catheter atherectomy) [52]. They found that 
the combination of strategies in this case was beneficial, as 
they observed early ST-segment resolution, early CK-MB 
peak, TIMI flow 3 and no evidence of distal embolization. 
Thus, several case reports and case series have suggested 
that ic administration of Abciximab is feasible – but based 
on these reports so far no definite evidence exists that ic ad-
ministration should be preferred. 
  As shown in Table 2 our search for clinical trials compar-
ing ic versus iv use of Abciximab resulted in only 5 studies, 
one small randomised prospective study with one month 
follow-up [53], one prospective control group matched study 
with in hospital follow-up [54], one observational study with 
a partly comparison of iv treated patients from other studies 
[55] and finally 2 retrospective studies [56,57].  
 Bellandi  et al. have presented the only randomized pro-
spective study [53]. In 2004 this study was published in 
which 45 consecutive patients with STEMI who underwent 
primary PCI were randomized to either ic or iv treatment 
with Abciximab. 22 of those were assigned to the ic-group. 
Angiographic myocardial blush grade, corrected TIMI frame 
count (CTFC) and reduction in ST segment elevation were 
used as markers of myocardial reperfusion. To assess initial 
perfusion defect, final infarct size, myocardial salvage, sal-
vage index, recovery of left ventricle (LV) and myocardial 
perfusion scintigraphy were performed at admission, after 7 
days and 1 month. A significant higher degree of myocardial 
salvage (ic: 20.4% of LV vs. iv: 11.0% of LV; P=0.0001) 
resulted in higher salvage index in the ic group (0.66 vs.
0.40; P=0.003). Also LV recovery improved more in the ic 
group after 1 month (14.7% vs. 8,0%, P=0.013). In addition a 
decrease in CTFC was observed.  
  The scintigraphic results led the authors to conclude that 
administering Abciximab ic in STEMI patients results in an 
increase of myocardial salvage and better left ventricular 
recovery.  
  The latest prospective study on the issue was performed 
by Ramagnoli et al. [54] and published in 2005. 37 consecu-
tive patients with ACS who underwent urgent PCI were 
Table 2.  Trials Evaluating Intravenous vs. Intracoronary Abciximab 
Author 
Year 
[ref.] 
N
o of Patients 
Studied 
iv/ic 
Population Design  Follow-up  Evaluation  Conclusion 
Belandi 
2004 [53] 
45
23/22 
STEMI Prospective. 
Randomized. 
7 days.  
1 month. 
IS, MS, SI, left ventricular function
recovery after 1 month. 
 in IS,  in MS, SI and 
LVEF in ic-group*. 
Romagnoli 
2005 [54] 
74
37/37 
STEMI 
NSTEACS 
Prospective. 
Control-group  
matched by base-
line-
characteristics.  
In-hospital. Angiographic by 
CTFC. 
Cardiac enzymes (CK, CK-MB, 
TNT). 
 in CTFC*. 
Trend towards  of peak 
enzyme values in ic-
group. 
 of CK-MB peak value 
in STEMI-subgroup in 
ic-group*. 
Wöhrle 
2007 [55] 
633 STEMI  Observational. 
Control: Other 
studies with no or 
iv-Abciximab 
30 days.  MACE (death, myocardial infarc-
tion, urgent TVR). 
Bleeding. 
 MACE in present study
vs. earlier iv-studies. 
No safety issues.  
Kakkar 
2004 [56] 
173
72/101 
Stable angina 
STEMI 
NSTEACS 
Retrospective. 6  months.  MACE (death, myocardial infarc-
tion). 
MACE  in ic-group, 
5.8% vs. 13.9%*. 
Wöhrle 
2003 [57] 
403
109/294 
Unstable 
angina 
STEMI 
NSTEACS 
Retrospective. 30  days.  MACE (death, myocardial infarc-
tion, urgent revascularization). 
MACE  in ic-group, 
10.2% vs. 20.2%*. 
* P<0.05. 
Abbreviations: CK: Creatin-kinase; CK-MB: Creatin-kinase-MB; CTFC: Corrected TIMI frame count; IS: Infarct Size; MACE: Major Adverse Cardiovascular events; MS: Myocar-
dial Salvage; NSTEACS: non-ST-elevation acute coronary syndrome; SI: Salvage Index; STEMI: ST-elevation myocardial infarction; TNT: Troponin T; TVR: Target vessel revas-
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given ic Abciximab. This population was matched by base-
line characteristics with 37 patients who were treated with iv 
Abciximab bolus. All 74 patients were routinely pre-treated 
with iv Abciximab. The 37 patients in the ic group were se-
lected at the discretion of the operator. No differences in 
angiographic baseline data were found. The angiograms 
were evaluated independently and blinded by two expert 
interventional cardiologists with respect to CTFC. In addi-
tion cardiac enzymes were collected. Significant decrease in 
CTFC was observed in the culprit vessel compared to the 
non-culprit vessel within the ic group in all subgroups 
(STEMI vs. NSTEACS, visible vs. no visible thrombus, and 
TIMI flow 0-1 vs. 2-3). The most pronounced improvement 
was seen when comparing visible vs. no visible thrombus 
with a 37% vs. 4% (P=0.008) reduction in CTFC, and TIMI 
0-1 versus 2-3 with a 34% vs. 21% (P=0.008) reduction in 
CTFC. A comparison between ic and iv administration of 
Abciximab was also performed. Baseline CTFC were similar 
in the ic and iv group. CTFC decreased significantly after ic-
administration of Abciximab compared to iv-administration 
(P=0.001), but only a trend towards improvement was seen 
in the ic group at the final CTFC (P=0.07). In this compari-
son cardiac enzymes (CK, CK-MB and TNT) were analysed 
also. A trend towards reduction of post-treatment peak-
values was seen in the ic-group, but only CK-MB in the 
STEMI-subgroup were found to be significantly different 
(P=0.03). The authors concluded that CTFC decreases when 
Abciximab is used ic compared to iv. No clinical follow-up 
data after discharge were presented.
  In the latest study [55], 633 STEMI patients were given 
ic Abciximab bolus during PCI. The patients were then di-
vided into two subgroups depending on their co-morbidity. 
Patients with high co-morbidity (failed thrombolysis, cardio-
pulmonary resuscitation, cardiogenic shock, advanced age or 
renal failure) were assigned to group II, whereas patients 
without these risk-factors were assigned to group I. The lat-
ter group was compared to earlier studies that compared iv 
bolus Abciximab to no Abciximab. The authors found that 
Major Adverse Cardiovascular Events (MACE) occurred in 
3.6% in group I which was lower compared to other random-
ized clinical studies evaluating iv bolus of Abciximab 
(RAPPORT 5.8% [58], ISAR-2 5.0% [59], ADMIRAL 6.0% 
[60], CADILLAC 4.4% [61] and ACE 4.5% [62]). A com-
parison between group I and II was performed with respect 
to MACE at 30 days and bleeding events. Not surprisingly 
group II had a higher incidence of both (MACE 3.6% in 
group I versus 31.9% in group II; bleeding, both minor and 
major 7.1% in group I versus 15.9% in group II). In conclu-
sion the authors stated that ic use of Abciximab is safe and 
that the incidence of MACE is lower compared to iv use. 
The limitation of this study is the observational design, the 
short follow-up of 30 days and the fact that the patients are 
compared to studies that were designed to compare Abcixi-
mab and placebo. However, the findings support the thesis of 
ic Abciximab being superior to iv.  
  In 2004 the study with the longest follow-up was per-
formed. Kakkar et al. [56] included 173 patients who had 
coronary stenting performed and received Abciximab. The 
population consisted of patients with stable angina, NSTACS 
or STEMI. At the discretion of the operator, 101 of those 
received ic bolus of Abciximab, 72 received iv bolus. All 
subsequently received a 12 h iv infusion of Abciximab. Data 
were collected retrospectively, and the ic and iv groups were 
compared. Patient and procedural characteristics in the ic and 
iv group were similar. Clinical end-points were defined as 
MI, death, TVR and rehospitalization within 6 months. 
When comparing the composite end-point of MI and death a 
borderline significant difference between ic and iv group was 
found (6% vs. 14%, P=0.08). After performing multiple lo-
gistic regression controlling for sex, race, diabetes, left ven-
tricular ejection fraction, age, smoking, hypertension and 
hyperlipidemia, a significant difference was found (ic: 6% 
vs. iv: 14%, P=0.04). No differences were found between the 
two groups regarding the individual end-points. No safety 
issues were recorded. The authors noted that ic Abciximab 
may be superior to iv with respect to the composite end-point 
of MI and death. However, the conclusion is limited by the 
fact that the study was relatively small and non-randomised, 
and that data were collected retrospectively. 
  The first study comparing ic vs. iv use of Abciximab was 
performed by Wöhrle et al. and published in 2003 [57]. In 
this rather large study of 433 patients with unstable angina, 
NSTEACS or STEMI, 294 patients had Abciximab bolus 
administered ic and the remaining 139 patients were treated 
with iv. The study was retrospective and non-randomized. 
Baseline characteristics were similar. MACE was defined as 
death, MI and urgent revascularization within 30 days. The 
main finding in this study was the significantly lower inci-
dence of MACE (ic: 10% vs. iv: 20%, P=0.008) which was 
probably part of the motivation for the later studies described 
above.  
FUTURE STUDIES 
  The studies described above all have in common that the 
authors call for randomized prospective studies to evaluate 
the efficacy and safety of ic administration of Abciximab. By 
searching www.clinicaltrials.gov we only found one ongoing 
study [63]. 
  The hypothesis in this study is that ic bolus Abciximab 
given during primary PCI in a STEMI population leads to 
higher iv concentration and thus improved epicardial flow 
and perfusion, and reduction of no-reflow and infarct size, 
and subsequently better outcome compared to iv bolus. The 
study is no longer recruiting participants.  
  At our centre at Gentofte University Hospital, Copenha-
gen, we are conducting a study with the purpose to evaluate 
the efficacy and safety of ic bolus Abciximab compared to iv 
bolus. To do so we plan to include 500 patients (of which 
360 have already been included) in a prospective randomised 
trial. Patients scheduled for PCI and who meet the usual cri-
terias for Abciximab will be randomised to either ic or iv 
bolus Abciximab. All patients receive the standard 12 h post-
PCI Abciximab iv infusion. Follow-up is after 1 month and 
one year. Clinical end-points are death, MI, angina, TVR and 
stroke. Incidence of bleeding is recorded. For further infor-
mation visit www.clinicaltrials.gov NCT00685464.  
CONCLUSION  
  Whether the optimal route of bolus Abciximab is iv or ic 
is still unclear. Existing evidence arguing for ic Abciximab is 298 Current Cardiology Reviews, 2008, Vol. 4, No. 4 Iversen et al. 
based first on relevant pharmacological rationale, second on 
a number of case reports, and third on 5 clinical studies on 
which no final conclusion can be drawn. 
  Therefore, randomised prospective studies testing the 
relevant hypothesis, that ic administration may be superior, 
are needed. 
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